Weekly Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Ratings on Jan 12, 2019

Big Money Sentiment decreased to 0.8 in 2018 Q3. It has change of 0.24, from 2018Q2’s 1.04. The ratio dropped due to Supernus Pharmaceuticals, Inc. positioning: 47 sold and 90 reduced. 35 funds bought stakes and 74 increased stakes. Investors holded 50.40 million in 2018Q2 but now own 48.83 million shares or 3.12% less.
Menta Lc invested in 7,559 shs or 0.13% of the stock. Rice Hall James And Assoc Lc has invested 1.15% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). 14,501 were accumulated by Campbell Newman Asset Mgmt Inc. Voya Invest Lc has 660,406 shs for 0.07% of their capital. Reilly Financial Advsrs invested in 0.01% or 1,500 shs. Metropolitan Life Ins Ny invested 0% of its capital in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Van Hulzen Asset Mngmt holds 0.15% of its capital in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 11,410 shs. Strs Ohio owns 0.02% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 79,800 shs. Victory Capital Mgmt Incorporated has invested 0% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Loomis Sayles & Com L P accumulated 573,212 shs. 1,200 were reported by First Mercantile Tru. Geode Cap Ltd Llc owns 543,991 shs. State Board Of Administration Of Florida Retirement Systems owns 0.01% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 64,678 shs. California State Teachers Retirement System stated it has 0.01% of its capital in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Baltimore holds 0.38% of its capital in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 41,630 shs.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Ratings Coverage

A total of 4 analysts rate Supernus Pharmaceuticals (NASDAQ:SUPN) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:SUPN) has 5 ratings reports on Jan 12, 2019 according to StockzIntelligence. The stock rating was maintained by Mizuho with “Buy” on Monday, December 17. On Monday, November 12 FBR Capital maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating. FBR Capital has “Buy” rating and $65 target. The company rating was maintained by Jefferies on Thursday, August 9. Listed here are Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) PTs and latest ratings.

17/12/2018 Broker: Mizuho Old Rating: Buy New Rating: Buy Old Target: $61 New Target: $63 Maintain
21/11/2018 Broker: SunTrust Rating: Buy New Target: $57.0000
12/11/2018 Broker: FBR Capital Old Rating: Buy New Rating: Buy Old Target: $68 New Target: $65 Maintain
18/09/2018 Broker: Mizuho Rating: Buy New Target: $61 Initiates Coverage On
09/08/2018 Broker: Jefferies Old Rating: Buy New Rating: Buy Old Target: $55 New Target: $58 Maintain

SUPN is reaching $37.72 during the last trading session, after increased 4.92%.Supernus Pharmaceuticals, Inc. has 624,533 shares volume, 1.99% up from normal. SUPN is uptrending and has moved 0.96% since January 12, 2018. SUPN outperformed the S&P 500 by 0.96%.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.The firm is valued at $1.97 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.20.65 is the P/E ratio. The companyÂ’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.